Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4555 - The Sarcoma Policy Checklist – focusing policy efforts on sarcoma


11 Sep 2017


Poster display session




Bernd Kasper


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


B. Kasper1, P.G.G. Casali2, N. Drove3, S. Dumont4, M. Eriksson5, A. Gronchi6, E. Lecointe7, C. Valverde Morales8, R. Wilson9, S. Boldon10, S. Wait11, M. Wartenberg12

Author affiliations

  • 1 Mannheim University Medical Center, University of Heidelberg, 68167 - Mannheim/DE
  • 2 Adult Mesenchymal Tumour And Rare Cancer Medical Oncology Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Oncology, Eli Lilly and Company, Madrid/ES
  • 4 Department Of Cancer Medicine, Institut de cancérologie Gustave Roussy, 94800 - Villejuif/FR
  • 5 Skåne University Hospital, Department of Oncology, 221 85 - Lund/SE
  • 6 Department Of Surgery, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 7 Infosarcomes, InfoSarcomes, Rennes/FR
  • 8 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 9 The Sarcoma Patients Euronet (spaen), The Sarcoma Patients Euronet (SPAEN), Shropshire/GB
  • 10 The Health Policy Partnership, The Health Policy Partnership, WC2N2JS - London/GB
  • 11 The Health Policy Partnership, The Health Policy Partnership, WC2N4JS - London/GB
  • 12 Spaen, SPAEN, Wölfersheim/DE


Abstract 4555


The Sarcoma Policy Checklist was developed by a multi-stakeholder group of experts to help policymakers prioritise actions to close the gap in access to high-quality information and care for sarcoma patients in Europe.


Experts defined five key areas where policy efforts are most needed to improve the care of sarcoma patients across Europe. A pragmatic review of the published literature was then conducted to determine to what extent recommendations were implemented in practice. Research focused on six countries (France, Germany, Italy, Spain, Sweden and the United Kingdom) and was complemented by local expert interviews.


Five key priority areas were identified by experts: Each country should have designated, accredited centres of reference for sarcoma; specialised professional training should be provided to all health care professionals involved in sarcoma care; a multidisciplinary approach to care should be offered to every patient; greater incentives for research and innovation, and more rapid access to effective treatments are needed. Most countries have specialist sarcoma centres, however, there is often a lack of defined criteria to designate specialist centres and evaluate the quality of care. Professional training is a gap in all countries, as training on rare cancers is most often not included in the general medical curriculum or in oncologists’ training. More basic research is needed to understand the underlying epidemiology of sarcomas, and help focus research on effective treatments. Greater alignment between regulatory frameworks and access frameworks such as Health Technology Assessment is needed, particularly in terms of evidentiary requirements for new treatments.


The heterogeneity of sarcomas poses particular challenges to research, professional training and patient access to quality treatment and care. The creation of the European Reference Network (ERN) on sarcoma, and recent advances in defining essential requirements and patient-driven principles for sarcoma care will help improve the situation of sarcoma patients across Europe. This policy paper hopes to contribute to those efforts and help drive meaningful policy change to improve patient care.

Clinical trial identification

Legal entity responsible for the study

The Health Policy Partnership Ltd


Eli Lilly and Company Europe


N. Drove: Employment with Eli Lilly and Company, the pharmaceutical company that is funding this project. S. Boldon: Consultancy fees from Eli Lilly and Company as an employee of the Health Policy Partnership, which has led the coordination and policy writing for this project. S. Wait: Consultancy fees from Eli Lilly and Company as managing director of the Health Policy Partnership, which has led the coordination and policy writing for this project. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.